Comment from Astrazeneca

Summary: AstraZeneca supports the draft guidance on Master Protocols for Drug and Biological Product Development, noting it is timely and supportive of innovation. The company suggests expanding the guidance to include more detail on basket trials, precision medicine, rare diseases, and practical considerations like patient centricity and sample size estimation.